Diabetes May Be Independent Risk Factor for Hyperkalaemia

Overview

Journal BMJ

Specialty General Medicine

Date 2003 Oct 4

PMID 14525902

Citations 9

Authors

Paul R Jarman

Hugh M Mather

Affiliations

Soon will be listed here.

Citing Articles

Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial.

Butler J, Siddiqi T, Anker S Eur J Heart Fail. 2022; 24(10):1744-1747.

PMID: 36088540 PMC: 9826001. DOI: 10.1002/ejhf.2684.

The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i.

Cianciolo G, De Pascalis A, Gasperoni L, Tondolo F, Zappulo F, Capelli I Molecules. 2020; 25(12).

PMID: 32549243 PMC: 7355461. DOI: 10.3390/molecules25122757.

Mineral and Electrolyte Disorders With SGLT2i Therapy.

Cianciolo G, De Pascalis A, Capelli I, Gasperoni L, Di Lullo L, Bellasi A JBMR Plus. 2019; 3(11):e10242.

PMID: 31768494 PMC: 6874177. DOI: 10.1002/jbm4.10242.

Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.

Bruno N, Sinagra G, Paolillo S, Bonomi A, Corra U, Piepoli M ESC Heart Fail. 2018; 5(3):267-274.

PMID: 29397584 PMC: 5933965. DOI: 10.1002/ehf2.12244.

Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.

Cooper L, Lippmann S, Greiner M, Sharma A, Kelly J, Fonarow G J Am Heart Assoc. 2017; 6(12).

PMID: 29275368 PMC: 5779000. DOI: 10.1161/JAHA.117.006540.

References

Odawara M, Asano M, Yamashita K . Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics. Diabet Med. 1997; 14(2):169-70. DOI: 10.1002/(SICI)1096-9136(199702)14:2<169::AID-DIA307>3.0.CO;2-5. View

Jarman P, Kehely A, Mather H . Hyperkalaemia in diabetes: prevalence and associations. Postgrad Med J. 1995; 71(839):551-2. PMC: 2398240. DOI: 10.1136/pgmj.71.839.551. View

Walmsley R, White G, Cain M, McCarthy P, Booth J . Hyperkalemia in the elderly. Clin Chem. 1984; 30(8):1409-12. View

Wrenger E, Muller R, Moesenthin M, Welte T, Frolich J, Neumann K . Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003; 327(7407):147-9. PMC: 1126510. DOI: 10.1136/bmj.327.7407.147. View